白云山：当前公司创新药研发管线推进有序

证券之星06-26

证券之星消息，白云山(600332)06月26日在投资者关系平台上答复投资者关心的问题。

投资者提问：请董秘介绍下待选职工代表董事刘宏院长主导或参与了那些创新药的研发，当前进展情况？

白云山回复：尊敬的投资者您好，感谢您的关注!刘宏先生是本公司职工代表董事、科研项目管理部部长，刘宏先生的简历详见公司于2026年5月16日披露的《关于选举职工代表董事的公告》。当前公司创新药研发管线推进有序，1类创新治疗领域涵盖慢性心力衰竭、妇科、抗感染、抗肿瘤、骨关节炎疾病等临床需求迫切的方向，着力满足未被充分满足的临床医疗需求，同时不断推进2类改良型新药研发工作。公司研发项目具体情况详见公司定期报告以及相关临时公告。

本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2646543353?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-26 17:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646543353","market":"fut","top_or_hot":-1,"title":"白云山：当前公司创新药研发管线推进有序","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/600332\">白云山</a>(600332)06月26日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：请董秘介绍下待选职工代表董事刘宏院长主导或参与了那些创新药的研发，当前进展情况？</p><p><a href=\"https://laohu8.com/S/00874\">白云山</a>回复：尊敬的投资者您好，感谢您的关注!刘宏先生是本公司职工代表董事、科研项目管理部部长，刘宏先生的简历详见公司于2026年5月16日披露的《关于选举职工代表董事的公告》。当前公司创新药研发管线推进有序，1类创新治疗领域涵盖慢性心力衰竭、妇科、抗感染、抗肿瘤、骨关节炎疾病等临床需求迫切的方向，着力满足未被充分满足的临床医疗需求，同时不断推进2类改良型新药研发工作。公司研发项目具体情况详见公司定期报告以及相关临时公告。</p><p>本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。</p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>白云山：当前公司创新药研发管线推进有序</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n白云山：当前公司创新药研发管线推进有序\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-26 17:15 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026062600031556.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，白云山(600332)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请董秘介绍下待选职工代表董事刘宏院长主导或参与了那些创新药的研发，当前进展情况？白云山回复：尊敬的投资者您好，感谢您的关注!刘宏先生是本公司职工代表董事、科研项目管理部部长，刘宏先生的简历详见公司于2026年5月16日披露的《关于选举职工代表董事的公告》。当前公司创新药研发管线推进有序，1类创新治疗...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026062600031556.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0097","symbol_name":"医药电商","start_time":0,"source_url":"https://stock.stockstar.com/RB2026062600031556.shtml","article_id":"2646543353","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646543353","pubTimestamp":1782465313,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"当前公司创新药研发管线推进有序，1类创新治疗领域涵盖慢性心力衰竭、妇科、抗感染、抗肿瘤、骨关节炎疾病等临床需求迫切的方向，着力满足未被充分满足的临床医疗需求，同时不断推进2类改良型新药研发工作。公司研发项目具体情况详见公司定期报告以及相关临时公告。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","600332":"白云山","BK0097":"医药电商","BK0239":"医药制造","BK1197":"保健护理产品经销商","BK1521":"挪威政府全球养老基金持仓","BK0096":"民营医院","BK0183":"MSCI概念","BK0188":"融资融券","00874":"白云山","BK0028":"国家队","BK1191":"制药","BK1161":"生物科技","BK0175":"白马股","BK0012":"证金概念","06978":"永泰生物-B","BK0070":"员工持股","BK1515":"抗疫概念","BK1606":"中医药概念","BK1574":"生物医药B类股","BK0196":"行业龙头"},"translate_title":"Baiyunshan: At present, the company's innovative drug R&D pipeline is advancing in an orderly manner","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"600332":1.5,"06978":1.5,"00874":1.5},"content_text":"证券之星消息，白云山(600332)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请董秘介绍下待选职工代表董事刘宏院长主导或参与了那些创新药的研发，当前进展情况？白云山回复：尊敬的投资者您好，感谢您的关注!刘宏先生是本公司职工代表董事、科研项目管理部部长，刘宏先生的简历详见公司于2026年5月16日披露的《关于选举职工代表董事的公告》。当前公司创新药研发管线推进有序，1类创新治疗领域涵盖慢性心力衰竭、妇科、抗感染、抗肿瘤、骨关节炎疾病等临床需求迫切的方向，着力满足未被充分满足的临床医疗需求，同时不断推进2类改良型新药研发工作。公司研发项目具体情况详见公司定期报告以及相关临时公告。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646543353","isCrawlerRequest":true}